0001104659-24-057003.txt : 20240503 0001104659-24-057003.hdr.sgml : 20240503 20240503163005 ACCESSION NUMBER: 0001104659-24-057003 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240430 FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Seurer Jerad G. CENTRAL INDEX KEY: 0002020970 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 24913629 MAIL ADDRESS: STREET 1: AVADEL PHARMACEUTICALS PLC STREET 2: 10 EARLSFORT TERRACE CITY: DUBLIN STATE: L2 ZIP: D02 T380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 3 1 tm2413417-1_3seq1.xml OWNERSHIP DOCUMENT X0206 3 2024-04-30 0 0001012477 AVADEL PHARMACEUTICALS PLC AVDL 0002020970 Seurer Jerad G. C/O AVADEL PHARMACEUTICALS PLC 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 IRELAND 0 1 0 0 Gen. Counsel & Corp. Secretary Ordinary Shares 8795 D Stock Option (Right to Buy) 9.67 2027-11-07 Ordinary Shares 25000 D Stock Option (Right to Buy) 7.55 2030-01-02 Ordinary Shares 30000 D Stock Option (Right to Buy) 6.79 2030-12-08 Ordinary Shares 80000 D Stock Option (Right to Buy) 8.20 2031-12-07 Ordinary Shares 47500 D Stock Option (Right to Buy) 4.69 2032-08-04 Ordinary Shares 100000 D Stock Option (Right to Buy) 13.57 2034-02-20 Ordinary Shares 125000 D Options fully vested and exercisable. Options become exercisable as to 20,000 ordinary shares on each of the first four anniversaries after the 12/8/2020 grant date. Options become exercisable as to 11,875 ordinary shares on each of the first four anniversaries after the 12/7/2021 grant date. Options become exercisable as to 50,000 ordinary shares on each of 6/1/2023 and 6/1/2024. Options become exercisable as to 31,250 ordinary shares on each of the first four anniversaries after the 2/20/2024 grant date. Exhibit 24 - Power of Attorney /s/ Jerad G. Seurer 2024-05-03 EX-24 2 tm2413417d1_ex24.htm EXHIBIT 24

Exhibit 24

 

POWER OF ATTORNEY

 

Know all by these presents, that the undersigned hereby constitutes and appoints Thomas S. McHugh, Senior Vice President and Chief Financial Officer of Avadel Pharmaceuticals plc, an Irish public limited company (the “Company”), and Robert Puopolo and Marishka DeToy both of Goodwin Procter LLP, with full power of substitution and re-substitution, to act as the undersigned’s true and lawful attorney-in-fact to:

 

  (1) prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the United States Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes, passwords, and passphrases enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any related rule or regulation of the SEC;

 

  (2) execute for and on behalf of the undersigned, in the undersigned’s capacity as a director and/or executive officer, as applicable, of the Company, Forms 3, 4, and 5 in accordance with Section 16(a) of the Exchange Act and the rules thereunder;

 

  (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such forms and amendments with the SEC and any securities exchange or similar authority; and

 

  (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and re-substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act and the rules thereunder.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 30th day of April, 2024.

 

  /s/ Jerad G. Seurer
  Jerad G. Seurer